Literatur
-
1
Parkinson Study Group .
A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study.
Arch Neurol.
2002;
59
1937-1943
-
2
Calker D van, Muller M, Hamprecht B.
Adenosine regulates via two different types of receptors: the accumulation of cyclic AMP in cultured brain cells.
J Neurochem.
1979;
33
999-1005
-
3 Hubble J P, Hauser R. A novel adenosine antagonist (KW-6002) as a treatment for advanced Parkinson's disease with motor complications. In: The 54th Annual Meeting of the American Academy of Neurology. Denver, Colorado; Neurology 2002
-
4 Sherzai A. et al .Adenosine A2a antagonist treatment of Parkinson's disease. In: The 54th Annual Meeting of the American Academy of Neurology. Denver, Colorado; Neurology 2002
-
5
Petzer J P. et al .
Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists.
Bioorg Med Chem.
2003;
11
1299-1310
-
6
Maswood N. et al .
Effects of chronic intraputamenal infusion of glial cell line-derived neurotrophic factor (GDNF) in aged Rhesus monkeys.
Neurobiol Aging.
2002;
23
881-889
-
7
Grondin R. et al .
Glial cell line-derived neurotrophic factor increases stimulus-evoked dopamine release and motor speed in aged rhesus monkeys.
J Neurosci.
2003;
23
1974-1980
-
8
Grondin R. et al .
Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys.
Brain.
2002;
125
2191-2201
-
9
Nutt J G. et al .
Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD.
Neurology.
2003;
60
69-73
-
10
Schwid S R. and the Parkinson Study Group .
CEP-1347 in Parkinson's disease: A pilot study.
Mov Disord.
2002;
17, Suppl 5
P259
Dr. med. W. H. Oertel
Klinik für Neurologie · Zentrum für Nervenheilkunde · Philipps-Universität
Rudolf-Bultmann-Straße 8
35033 Marburg
eMail: oertelw@mailer.uni-marburg.de